Hepatobiliary and pancreatic carcinomas are hypovascular tumors that can proliferate under hypoxic conditions. Recent reports have demonstrated that hypoxia-inducible factor 1 alpha (HIF1a) plays an important role in the survival of these cancers. Given these findings, the inhibition of the HIF1a pathway might prove to be a powerful tool in the treatment of these cancers. To inhibit HIF1a expression, we used small interference RNA (siRNA) expression vectors in this study. The transient transfection of siRNA expression vectors significantly reduced both HIF1a mRNA levels (13% of control) and protein levels (41% of control) and significantly inhibited the growth of cancer cell lines (Po0.05). VEGF, Glut1, and aldorase A expressions were also significantly reduced by transfection with these vectors (Po0.05), and we found that these vectors induced apoptosis but not cell cycle arrest. In a subcutaneous tumor model using nude mice, transfected MIA PaCa-2 cells, stably expressing siRNAs, barely formed tumors compared to control (Po0.05). This study thus demonstrates the usefulness of siRNA expression vector in targeting HIF1a and points to a potential clinical role in the treatment of pancreatic and hepatobiliary carcinomas.
Introduction
Solid tumors are highly dependent upon angiogenesis for their survival. However, in tumors such as pancreatic and hepatobiliary carcinomas, the newly formed vasculature is often immature and unable to supply sufficient oxygen and nutrients to rapidly dividing tumor cells. Nonetheless, these cancers are able not only to survive but also proliferate, growing under more hypoxic conditions than corresponding normal tissues.
Under these hypoxic conditions, one of the major factors influencing tumor growth is the hypoxia-inducible factor 1 alpha (HIF1a). HIF1a is a basic helix-loop-helix/ PAS transcription factor that forms a dimer with the Ah receptor nuclear translocator (ARNT) and binds to elements responsible for hypoxia. 1 Under normal oxygen conditions, HIF1a is ubiquitinated and degraded by modifications from prolyl hydroxylase and interaction with the Von Hippel-Lindau (VHL) protein. 2 When the oxygen content of the surroundings decreases, HIF1a degradation is suppressed by the inactivation of prolyl hydroxylase, and HIF1a transcription accelerates. Additionally, HIF1a can activate a large number of other genes, such as VEGF, glucose transporters, glycolytic pathway enzymes, erythropoietin, and inducible nitric oxide synthase. 3 Recently, it has been reported that the increased expression of HIF1a protein correlates with tumor progression and prognosis in several types of tumors. [4] [5] [6] [7] It would appear, then, that inhibiting the HIF1a protein can block angiogenesis and glycolytic metabolism in solid tumors, thus suppressing tumor growth and metastasis.
In order to inhibit HIF1a expression, various technologies have been considered. [8] [9] [10] One such technology, RNA interference (RNAi), is the process of sequencespecific post-transcriptional gene silencing that has been performed in various organisms, including Drosophila and Caenorhabditis elegans. This technique, however, has been limited in mammalian cells because of nonspecific gene silencing that results from a physiological reaction involving an interferon pathway. 11 However, it has recently been reported that small interfering RNAs (siRNAs), 21-23 nucleotide RNAs with two to three overhangs, exhibit gene-specific RNAi without activating the nonspecific interferon pathway in mammalian cells. 12 These siRNAs have been demonstrated to have stronger suppressive effects than antisense oligonucleotides. 13 Furthermore, recent studies have demonstrated that siRNA expression vectors that transcribe siRNAs by the U6 or H1 promoters more effectively suppress the expression of endogenous genes and exhibit more persistent inhibition compared to synthetic siRNAs. [14] [15] [16] [17] [18] [19] [20] [21] Given these findings, siRNAs may have applicability in mammalian cells, as well as a potential role in gene targeting therapy. In this study, we focus on the siRNA expression vector as a tool to inhibit HIF1a expression and investigate its usefulness in in vitro and murine models of hepatobiliary and pancreatic carcinomas.
Materials and methods
siRNA expression plasmids Tandem-type and hairpin-type siRNA expression vectors using the pU6icassette vector, 14 which contains a human U6 promoter and two BspMI sites, were prepared. For the construction of tandem-type siRNA expression plasmids, we used polymerase chain reaction (PCR) to amplify DNA fragments that included the HIF1a target sequences of the sense and antisense regions and the U6 promoter using the pU6icassette vector as a template. After digestion of its products, each fragment was ligated into the BspMI sites of the pU6icassette vector to yield a series of siRNA expression vectors. For the construction of hairpin-type siRNA expression plasmids, we synthesized oligonucleotides with the hairpin sequence, the terminator sequence, and overhanging sequences. Then, we annealed the fragments and inserted them into the BspMI sites of the pU6icassette vector. The target sequence selections were based on the characterization of siRNA by Elbashir et al. 22 PCEP4siHIFno5 vectors were generated using PCR-based subcloning of the pU6iHIFno5 vector into the pCEP4 vector (Invitrogen Corp., Carlsbad, CA).
Cell culture conditions and transfection of plasmids Three pancreatic carcinoma cell lines (MIA PaCa-2, PK-8, and PANC-1), two cholangiocarcinoma cell lines (TFK-1 and HuCCT1 (Cell Resource Center for Biomedical Research, Tohoku University)), and one hepatoma cell line (HepG2) were used. The cell lines were maintained in Dulbecco's modified Eagle's Medium (DMEM)/F12 medium with 10% heat-inactivated FBS at 371C in a humidified atmosphere of 5% CO 2 .
When cells reached 80-90% confluence, they were transfected with plasmids in the following manner using Lipofectamine 2000 reagent (Invitrogen Corp., Carlsbad, CA) according to the manufacturer's instructions. A 1.5 mg portion of plasmid was mixed in 100 ml of Opti-MEM medium (Invitrogen Corp., Carlsbad, CA), and 4.0 ml of the Lipofectamine 2000 reagent was diluted in another 100 ml of Opti-MEM medium and incubated for 5 min at room temperature. Then, both mixtures, one containing plasmid in Opti-MEM and the other containing Lipofectamine 2000 in Opti-MEM, were combined and incubated for 20 min at room temperature. This complex was added to cell cultures in 12-well dishes. After incubation for 18 h, the medium was removed and DMEM with 10% FBS was added. Incubation was continued in 20% O 2 (normoxia) or 1% O 2 (hypoxia) conditions.
Northern blot analysis
Total RNA was extracted from cultured cells using an ISOGEN kit (Nippon Gene Ltd, Toyama, Japan). Aliquots (20 mg) were electrophoresed on 1.5% agaroseformaldehyde gels, transferred to nylon membranes (Hybond N plus, Amersham, Buckinghamshire, UK), and then hybridized with 1 Â 10 6 c.p.m./ml of the 32 Pradiolabeled HIF1a cDNA probe. The probe was prepared using the DNA labeling kit (d-CTP) (Pharmacia Biotech Inc., Uppsala, Sweden) in Rapid-hyb buffer (Amersham, Buckinghamshire, UK) and 100 mg/ml salmon testis DNA at 651C for 2 h. Membranes were washed twice in 0.2 Â saline-sodium citrate buffer (SSC) and 0.1% sodium dodecyl sulfate (SDS) at 651C for 30 min. Then, HIF1a expression levels were analyzed and quantified by densitometric methods with a BAS 1000 image analyzer (Fuji Photo Film Co. Ltd, Minato-ku, Tokyo, Japan).
Next, the Northern blots were reprobed with a glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA probe to confirm that similar amounts of RNA were loaded and transferred from each sample. Within each sample, the density of the HIF1a mRNA band was determined by comparing the densities of GAPDH bands.
Western blot analysis Cells (2 Â 10 7 cells) were collected by centrifugation and resuspended in lysis buffer. Lysis buffer consisted of 10 mM Tris-HCl, 1 mM EDTA, 10 mM KCl, 10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 100 mM iodoacetamide, and 0.02% sodium azide. Samples were homogenized and placed on ice for 15 min. All lysates were centrifuged for 15 min at 41C, and then the supernatant was collected and stored at 41C as whole cell protein lysates. The protein concentration was measured spectrophotometrically using protein standards. An equivalent amount of Laemmli buffer was added to 20 mg of protein and then boiled for 3 min prior to loading. SDS-polyacrylamide gel electrophoresis was performed using a 7.5% resolving gel. Proteins were electrophoretically transferred to a nitrocellulose membrane in Tris-glycine buffer. Immunodetection was carried out using Immuno Star reagents (Wako, Osaka, Japan). The first antibody was a mouse monoclonal anti-HIF1a antibody (H1a67, Novous Biologicals Inc., Littleton) at 1/750 dilution.
Semiquantitative reverse transcription-polymerase chain reaction analysis Total RNA was extracted as above. After DNaseI treatment, first-strand cDNA was prepared using Omniscript Reverse Transcriptase (QIAGEN, Hilden, Germany) and oligo dT primers. Adequate PCR cycle numbers were chosen in the middle of an exponential range of amplification. The following oligonucleotides were used as primers: HIF1a, 5
0 -CCTGCACTCAAT CAAGAAGTTGC-3 0 (forward) and 5 0 -TTCTGCTCTG TTTGGTGAGGCT-3 0 (reverse) resulting in a 619 bp fragment; b-actin, 5
0 -ATCAAGATCCTGACCGAGC G-3 0 (forward) and 5 0 -TACTTGCGCTCAGGAGGAG C-3 0 (reverse) resulting in a 400 bp fragment; VEGF, 5 0 -GAAGTGGTGAAGTTCATGGATGTC-3 0 (forward) and 5
0 -CGATCGTTCTGTATCAGTCTTTCC-3 0 (reverse) resulting in a 365 bp fragment; Glut1, 5 0 -ATGAAGGAA GAGAGTCGGCA-3 0 (forward) and 5 0 -TGAAGAGTT CAGCCACGATG-3 0 (reverse) resulting in a 457 bp fragment; aldorase A, 5
0 -CACTGGGATCACCTTCC TGT-3 0 (forward) and 5 0 -AAGACACCACACACCACT GT-3 0 (reverse) resulting in a 412 bp fragment. The density of each band with background subtraction was measured using an NIH image. The levels of each kind of mRNA were normalized according to the density of b-actin bands.
Colony formation assay
Plasmid-transfected cells (1 Â 10 5 cells/100 mm dish) were incubated in medium. Approximately 2 weeks later, cell colonies were rinsed with phosphate-buffered saline (PBS), fixed with 5% glutaraldehyde (Nacalai Tesque, Kyoto, Japan) in PBS, and then stained with 0.2% crystal violet (Wako, Osaka, Japan) and 100 mM CAPS (Wako, Osaka, Japan). Colonies containing at least 50 cells were counted.
Cell cycle and apoptosis analysis Cell cycle distribution was assayed by determining DNA content. To determine DNA content, incubated cells were fixed using the dropwise addition of methanol at 41C. After fixation, cells were washed with PBS, and incubated for 30 min at room temperature with RNase (1 mg/ml) and propidium iodide (50 mg/ml). Before performing flow cytometric analysis, samples were filtered through a 35-mm nylon mesh. Stained cells were analyzed with a FACScan 83178 cytometer (Becton Dickinson, San Jose, CA). This assay was independently carried out three times.
We performed Hoechst 33342 staining for analysis of apoptosis. To detect apoptotic bodies, cells were fixed with 1% glutaraldehyde in PBS at 41C, washed twice with PBS, stained with 0.2 mM Hoechst 33342 (Sigma Chemical Co., St Louis, MO), and then observed under a fluorescence microscope. Apoptotic bodies were counted at three different fields of microscopic observation. A total of 100 cells were judged under one field. This assay was independently carried out three times.
In vivo tumor treatment
We transfected pCEP4siHIFno5 into MIA PaCa-2 cell lines using Lipofectamine 2000, and these cells were cultured in DMEM with 10% FBS and hygromycin. They were harvested from continuous culture and resuspended in DMEM without FBS for inoculation into nude mice. Male BALB/C-nu/nu mice (4-week-old) (Oriental BioService Inc., Kyoto, Japan) were injected subcutaneously with 1 Â 10 7 MIA PaCa-2 cells. Tumor volume was measured in a blind fashion using calipers. Tumor volume (TV) was estimated using the following formula: TV ¼ (A 2 B)/2, where A is the width (mm) of the tumor and B is its length (mm).
Immunohistochemical staining and counting of microvasculature CD31 was detected using a monoclonal antibody directed against CD31 (Becton Dickinson, San Jose, CA; 1:100 dilutions). The resected specimens were snap-frozen in liquid nitrogen and stored at À801C until analysis. Cryosections were air-dried and fixed for 10 min in cold acetone and then washed in PBS. The endogenous peroxidase activity was blocked with methanol containing 0.3% hydrogen peroxidase for 20 min. After another washing, the sections were preincubated in blocking serum and then incubated for 60 min at room temperature with the primary monoclonal antibody. Immunostaining was performed using the Histofine Simple Stein kit (Nichirei Co., Tokyo, Japan), a labeled polymer method. The staining was visualized with diaminobenzidine-tetrachloride. The sections were finally counterstained with hematoxylin. To assess microvasculature, the vessels in the four most highly vascularized areas were counted at Â 200 magnification, and the average count was calculated.
Apoptotic labeling index in vivo
The TUNEL assay was performed twice, according to the manufacturer's instructions, on each cryosection in order to detect fragmented DNA in situ (Apoptag Plus peroxidase kit, Oncor, Gaithersburg, MD). In each examination, at least 500 tumor cells were counted, and the apoptotic index, which was defined as the ratio of apoptosis cells against counted cells, was calculated as the mean of the two counts.
Statistical analysis
Statistical analysis was performed using the Student's t-test (two-tailed) throughout the present study. A P-value of o0.05 was considered statistically significant.
Results
Expression of HIF1a protein in hepatobiliary and pancreatic cancer cell lines As shown in Figure 1 , hypoxia strongly induced HIF1a protein expression in all cell lines. Under normoxic conditions, the HIF1a protein was undetectable in HepG2 cells. However, pancreatic cancer cells and cholangio-carcinoma cells expressed HIF1a protein under normoxia, especially the MIA PaCa-2 cells. Given this finding, MIA PaCa-2 was primarily used in our experiments.
Effects of HIF1a siRNA expression vectors on the MIA PaCa-2 cell line in culture siRNA expression vectors were designed to target five different HIF1a mRNA sequences (AF304431) ( Table 1) . Transfection efficiency in MIA PaCa-2 cells was about 78%, calculated using the pEGFP-N1 vector (BD Bioscience, Clontech, CA). The PU6iGL3 vector targeting the firefly luciferase GL3 was used as a control. After 48 h of culture, two of the five siRNA expression vectors, pU6iHIFno3 and pU6iHIFno5, both stem loop type vectors, effectively suppressed the expression of HIF1a mRNA and protein in MIA PaCa-2 cells (Figures 2 and  3) . PU6iHIFno4 also suppressed expression of both HIF1a and GAPDH mRNA at any time, although we performed this assay independently three times. Considered somewhat influence was reacted, pU6iHIFno4 was omitted. Densitometric analysis of the blots revealed that pU6iHIFno5 suppressed HIF1a mRNA and protein expression such that their expression was 13 and 41%, respectively, of that of control cultures.
Suppression of HIF1a, VEGF, Glut1, and aldorase A mRNA expression after transfection of HIF1a siRNA expression vectors We investigated the expression of genes activated by HIF1a, such as VEGF, Glut1, and aldorase A, using reverse transcription-polymerase chain reaction (RT-PCR). As shown in Figure 4 , hypoxia for 5 days induced expression of Glut1 and aldorase A. After transfection with HIF1a siRNA expression vectors, the levels of HIF1a mRNA and the expression of its related genes were suppressed over 5 days under normoxic as well as hypoxic conditions. After transfection with HIF1a siRNA expression vectors, levels of expression of HIF1a and its inducible genes were reduced under hypoxia to levels equivalent to those expressed under normoxia. On the other hand, the suppressive effect of these vectors disappeared in measurements of all related genes except for HIF1a after 2 days (data not shown).
Cell cycle analysis and apoptosis Analyses of cell cycle distribution 5 days after transfection are shown in Figure 5a . Hypoxia increased the proportion of the G1 peak in DNA content compared to normoxic conditions. Transfection with pU6iHIFno3 and Cancer gene therapy using HIF1alpha siRNAs T Mizuno et al pU6iHIFno5 decreased the proportion of the G1 peak under hypoxia. Furthermore, transfection with these vectors significantly increased the area of the less than G1 peak and the number of Hoechst 33342-stained cells compared to control (Figure 5b ).
Colony formation assay
The colony formation assay was used to investigate the inhibitory effects on growth of HIF1a siRNA expression vectors in a hypoxic environment. The effects on growth of these vectors in three pancreatic carcinoma cell lines, Cancer gene therapy using HIF1alpha siRNAs T Mizuno et al two cholangiocarcinoma cell lines, and a hepatoma cell line were investigated. Because transfection efficiency differed, siRNA expression vectors were cotransfected with the pEGFP-N1 vector that contains the neomycin resistance gene. Cells were cultured in medium with G418 sulfate (Invitrogen Co., Carlsbad, CA), which is inactivated by neomycin resistance gene, to eliminate any nontransfected cells. After incubation for 2 weeks, almost all cell lines grew more efficiently under hypoxic conditions compared to normoxic ones. Interestingly, the HIF1a siRNA expression vectors prevented several cell lines from forming colonies ( Figure 6 ). In particular, these vectors inhibited the growth of MIA PaCa-2, PK-8, TFK-1, and HuCCT1 under both normoxic and hypoxic conditions. Conversely, these vectors barely inhibited the growth of HepG2 under either condition.
Effect of siRNA expression vector on tumor growth in vivo
The inhibitory effects on growth were investigated in vivo. In order to establish stable transfectants, the pGEP4si-HIFno5 vector was generated by PCR-based subcloning Cancer gene therapy using HIF1alpha siRNAs T Mizuno et al of the pU6iHIFno5 vector into the pCEP4 vector, using the Epstein-Barr virus nuclear antigen 1 (EBNA-1)/Ori-P system. As shown in Figure 7a , the expression of the HIF1a protein decreased in pCEP4siHIFno5-transfected cells compared with control vector (pCEP4)-transfected cells and compared with cells that were not transfected at all. Transfected cells and cells that had no treatment were inoculated subcutaneously into male nude mice. Although the inoculations of control vector-transfected cells developed into massive tumors, those mice that received the pCEP4siHIFno5-transfected cells barely formed palpable tumors (Figure 7b ).
Apoptosis index and microvasculature staining in vivo
As shown in Figure 7c , the pCEP4siHIFno5-transfected cells showed a significantly higher apoptotic index than cells that were not transfected or those transfected with the pCEP4 vector (P ¼ 0.003). In microvasculature staining, a single vessel was defined as a row of brown immunostained endothelial cells that was separate from adjacent vessels, tumor cells, or other connective tissue elements. The number of microvessels in pCEP4siHIFno5-transfected cells was not different compared to the numbers in controls (Figure 7d ).
Discussion
In this study, we demonstrate how siRNA technology can be used to decrease HIF1a expression, thus inhibiting solid tumor growth. Although chemically synthesized siRNAs are powerful and convenient tools of gene silencing, they can also be problematic. Cancer gene therapy using HIF1alpha siRNAs T Mizuno et al effective as chemically synthesized siRNAs in inhibiting gene expression, the inhibitory effect of chemically synthesized siRNAs lasts only 1 week. The potential clinical application of siRNA technology requires an inhibitory effect of long duration. For these reasons, we chose not to use chemically synthesized siRNAs and instead created siRNA expression vectors to suppress HIF1a expression.
We synthesized two different types of siRNA expression vectors. One is a tandem-type vector that uses the U6 promoter to direct synthesis of sense and antisense siRNAs. The other is a stem loop type vector that uses the U6 promoter to direct the synthesis of short hairpin RNA molecules (shRNAs). ShRNAs have a doublestrand stem of 23 bp connected by a loop of nine bases and can be efficiently re-formed into siRNAs. 23 Although we did not compare two types of siRNA expression vectors using the same sequences, the stem loop type vector is likely to be more effective than the tandem type in gene silencing. Further studies on the different inhibitory effects of vector types should be carried out in the future.
The RNAi's, including siRNA, are extremely useful tools in gene targeting therapy and have revolutionized genetic studies. However, attention must be paid to selection of the most appropriate siRNA sequence, as RNAi's occasionally inhibit not only the target gene but also other nontarget genes. 24 Indeed, the PU6iHIFno4 vector suppressed GAPDH expression as well as HIF1a mRNA at any time in this study, although we performed Northern blotting three times. Both the pU6iHIFno3 vector and the pU6iHIFno5 vector were confirmed not to suppress other genes of this study except for HIF1a. Prior to the application of siRNA technology, these inhibitory effects against nontarget genes must be investigated.
Several studies have demonstrated the relationship between HIF1a expression and human cancer progression. [4] [5] [6] [7] 25, 26 Some of the solid tumor cell lines used in this study expressed the HIF1a protein under not only hypoxia but also normoxia. Therefore, the transfection of HIF1a siRNA expression vectors exhibited similar 27 Some tumors have been reported to have mutations of two domains in pVHL, thus stabilizing HIF1a in normoxia. 28 From the result of Figures 2 and 3 , pU6iHIFno5 suppressed HIF1a mRNA expression to 13% of control but HIF1a protein expression to only 41%. This dissociation of suppressive effect may result from difference of half-value period between HIF1a mRNA and protein, due to the reduction of degradation in HIF1a protein. In addition, mutations of the oxygen-dependent degradation domain, one that confers oxygen-dependent instability, in the HIF1a gene have been reported in renal cell carcinomas. 29 PU6iHIF-no5 prevented almost all cell lines besides HepG2 from forming colonies in this study, but pU6iHIFno3 did not prevent Panc-1 cells from forming colonies. This result may imply the presence of mutation of HIF1a gene near the target sequence of pU6iHIFno3. If different types of solid tumors are found to have specific mutations in HIF1a, gene therapy may be rendered tumor specific by constructing siRNA expression vectors that target these exact mutation sequences.
In our study, gene transfer of HIF1a siRNA expression vectors prevented cancer cell lines from forming colonies in vitro and from developing into solid tumors in vivo. Recent studies have reported that hypoxia could change cell proliferation in two distinct ways. One way is through apoptosis, and the other is through growth arrest in the G1 phase. [30] [31] [32] HIF1a has been shown to have both antiapoptotic and proapoptotic effects according to cell type and experimental conditions. [33] [34] [35] The analysis of cell cycle in this study showed that the transfection of pU6siHIFno3 and pU6siHIFno5 increased the area of the less than G1 peak and of Hoechst 33342-stained cells, confirming the induction of cell death by these transfections. These results suggest that transfection with these vectors did not cause G1 arrest in hypoxia but instead caused apoptosis to occur and that HIF1a had an antiapoptotic effect in pancreatic cancer cell lines. In addition, there were no differences in the number of Ki67 staining cells between those tumors transfected with siRNA expression vectors targeting HIF1a and those transfected with the control vector in vivo (data not shown). Taken together, the inhibition of HIF1a protein product results predominantly in apoptosis and not in cell cycle arrest. The induction of apoptosis may result from the suppression of genes activated by HIF1a, such as VEGF, aldorase A, and Glut1. VEGF is one of the most important genes induced by HIF1a and promotes angiogenesis. Figure 7d suggests that there was no significant difference in angiogenesis between tumors transfected with pCEP4siHIFno5 and those transfected with pCEP4. Recent reports have demonstrated that inhibition of HIF1a suppressed tumor formation without suppressing angiogenesis. 36 Baek et al. 37 reported that VEGF exhibited an antiapoptotic effect on tumors under hypoxic conditions. Given these findings, the induction of apoptosis that occurred in our study after transfection with siRNA expression vectors may have resulted primarily from the inhibition of VEGF expression.
In conclusion, we have demonstrated that siRNA expression vectors can inhibit the expression of HIF1a and of those genes induced by HIF1a, thus effectively suppressing the in vitro and in vivo growth of selected hepatobiliary tumors.
